Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stop Trial 2.0: Zanubrutinib and Sonrotoclax in Untreated CLL/SLL
NCT07682415Phase 2Not yet recruiting
- Sponsor
- Yishuhua
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of sonrotoclax and zanubrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Yishuhua. Primary endpoint: Undetectable Minimal Residual Disease Rate at 96 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07682415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07682415.